© 1995 by Oxford University Press
Journal of the National Cancer Institute, Vol. 87, No. 18, 1372-1382,
September 20, 1995
© 1995 Oxford University Press
Base-Line Quality-of-Life Assessment in the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial
Schools of Medicine and Public Health, and the Jonsson Comprehensive Cancer Center, University of California at Los Angeles Boston, MA
Department of Biostatistics, Graduate School of Public Health, and the National Surgical Adjuvant Breast and Bowel Project [NSABP] Biostatistical Center Boston, MA
NSABP Scientific Director, Operations Center, University of Pittsburgh PA
New England Medical Center Boston, MA
Correspondence to: Patricia A. Ganz, M.D., Division of Cancer Prevention and Control Research, Jonsson Comprehensive Cancer Center at UCLA, 1100 Glendon Ave., Suite 711, Los Angeles, CA 90024.
Background: The Breast Cancer Prevention Trial (BCPT) is a large, multicenter chemoprevention trial testing the efficacy of the antiestrogen drug tamoxifen for prevention of breast cancer and coronary heart disease in healthy women at high risk of breast cancer. The BCPT evolved from a series of prior studies in early stage breast cancer demonstrating the efficacy of tamoxifen in the prevention of systemic breast cancer recurrence and in the reduction of contralateral breast cancers. Purpose: The purpose of this article is to describe the methodologic considerations in the collection of health-related quality-of-life (HRQL) data in the BCPT and to present base-line HRQL data on the first 9749 participants. Methods: An HRQL questionnaire that included the Center for Epidemiologic Studies-Depression Scale, a symptom checklist, the Medical Outcomes Study 36-item short form (MOS-SF-36), and the MOS sexual problems questions was completed by participants in the BCPT at base line (prior to random assignment). Medical and demographic information, as well as projected risk of breast cancer, were collected as part of study eligibility. Descriptive and correlational data were examined for these study participants. Results: BCPT participants report high levels of functioning compared with U.S. general population norms but still report an average of 8.9 distinct symptoms during the past 4 weeks. Depression is less prevalent among the participants than in community samples, which reflects the exclusion of clinically depressed individuals. Sixty-five percent reported being sexually active in the past 6 months, with an age-related decline in sexual activity. Younger women reported fewer sexual problems than older women. There is a strong correlation between the two mental health measures, moderate to weak correlations between HRQL scales and levels of self-reported symptoms, and only weak correlations between measures of breast cancer risk and HRQL scales. The MOS-SF-36 scores were examined for three consecutive recruitment samples (0-6 months, 7-12 months, and 13-20 months), and the base-line scores were slightly better for the earliest group of participants. Conclusions: This article demonstrates the feasibility of collecting HRQL data in a large, multicenter, chemoprevention trial for women at high risk of breast cancer. The successful integration of HRQL data collection into this clinical trial attests to its value as a safety-monitoring end point and as an explicit and measurable outcome for the entire trial. Implications: HRQL data are important for studies in which healthy populations are involved and in which the potential for decrements in quality of life are real or perceived. [J Natl Cancer Inst 1995;87:1372-82]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. J. Crandall, A. K. Aragaki, R. T. Chlebowski, A. McTiernan, G. Anderson, S. L. Hendrix, B. B. Cochrane, L. H. Kuller, and J. A. Cauley New-Onset Breast Tenderness After Initiation of Estrogen Plus Progestin Therapy and Breast Cancer Risk Arch Intern Med, October 12, 2009; 169(18): 1684 - 1691. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Crespi, P. A. Ganz, L. Petersen, A. Castillo, and B. Caan Refinement and Psychometric Evaluation of the Impact of Cancer Scale J Natl Cancer Inst, November 5, 2008; 100(21): 1530 - 1541. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Goodwin, S. J. Green, C. M. Moinpour, J. D. Bearden III, J. K. Giguere, C. S. Jiang, S. M. Lippman, S. Martino, and K. S. Albain Phase III Randomized Placebo-Controlled Trial of Two Doses of Megestrol Acetate as Treatment for Menopausal Symptoms in Women With Breast Cancer: Southwest Oncology Group Study 9626 J. Clin. Oncol., April 1, 2008; 26(10): 1650 - 1656. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Ganz and C. C. Gotay Use of Patient-Reported Outcomes in Phase III Cancer Treatment Trials: Lessons Learned and Future Directions J. Clin. Oncol., November 10, 2007; 25(32): 5063 - 5069. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. N. Weitzel, S. S. Buys, W. H. Sherman, A. M. Daniels, G. Ursin, J. R. Daniels, D. J. MacDonald, K. R. Blazer, M. C. Pike, and D. V. Spicer Reduced Mammographic Density with Use of a Gonadotropin-Releasing Hormone Agonist-Based Chemoprevention Regimen in BRCA1 Carriers Clin. Cancer Res., January 15, 2007; 13(2): 654 - 658. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Leining, S Gelber, R Rosenberg, M Przypyszny, E. Winer, and A. Partridge Menopausal-type symptoms in young breast cancer survivors Ann. Onc., December 1, 2006; 17(12): 1777 - 1782. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Land, D. L. Wickerham, J. P. Costantino, M. W. Ritter, V. G. Vogel, M. Lee, E. R. Pajon, J. L. Wade III, S. Dakhil, J. B. Lockhart Jr, et al. Patient-Reported Symptoms and Quality of Life During Treatment With Tamoxifen or Raloxifene for Breast Cancer Prevention: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial JAMA, June 21, 2006; 295(23): 2742 - 2751. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Burwell, L. D. Case, C. Kaelin, and N. E. Avis Sexual Problems in Younger Women After Breast Cancer Surgery J. Clin. Oncol., June 20, 2006; 24(18): 2815 - 2821. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. A. Bardwell, L. Natarajan, J. E. Dimsdale, C. L. Rock, J. E. Mortimer, K. Hollenbach, and J. P. Pierce Objective Cancer-Related Variables Are Not Associated With Depressive Symptoms in Women Treated for Early-Stage Breast Cancer J. Clin. Oncol., June 1, 2006; 24(16): 2420 - 2427. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. E. Avis, S. Crawford, and J. Manuel Quality of Life Among Younger Women With Breast Cancer J. Clin. Oncol., May 20, 2005; 23(15): 3322 - 3330. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Stanton, C. A. Bernaards, and P. A. Ganz The BCPT Symptom Scales: A Measure of Physical Symptoms for Women Diagnosed With or at Risk for Breast Cancer J Natl Cancer Inst, March 16, 2005; 97(6): 448 - 456. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Mandelblatt, C. Armetta, K. R. Yabroff, W. Liang, and W. Lawrence Descriptive Review of the Literature on Breast Cancer Outcomes: 1990 Through 2000 J Natl Cancer Inst Monographs, October 1, 2004; 2004(33): 8 - 44. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. T. Veit A Single Mathematical Model Predicts Physicians' Recommendations and Postmenopausal Women's Decisions to Participate in a Clinical Trial to Prevent Breast Cancer or Coronary Heart Disease Med Decis Making, August 1, 2004; 24(4): 330 - 350. [Abstract] [PDF]
|
|
|
|
|
|
K. L. Taylor, R. Shelby, E. Gelmann, and C. McGuire Quality of Life and Trial Adherence Among Participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial J Natl Cancer Inst, July 21, 2004; 96(14): 1083 - 1094. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. W. Brawley The Study of Accrual to Clinical Trials: Can We Learn From Studying Who Enters Our Studies? J. Clin. Oncol., June 1, 2004; 22(11): 2039 - 2040. [Full Text] [PDF]
|
|
|
|
|
|
P. A. Ganz, L. Kwan, A. L. Stanton, J. L. Krupnick, J. H. Rowland, B. E. Meyerowitz, J. E. Bower, and T. R. Belin Quality of Life at the End of Primary Treatment of Breast Cancer: First Results From the Moving Beyond Cancer Randomized Trial J Natl Cancer Inst, March 3, 2004; 96(5): 376 - 387. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Cullen, M. D. Schwartz, W. F. Lawrence, J. V. Selby, and J. S. Mandelblatt Short-Term Impact of Cancer Prevention and Screening Activities on Quality of Life J. Clin. Oncol., March 1, 2004; 22(5): 943 - 952. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Ganz, G. A. Greendale, L. Petersen, B. Kahn, and J. E. Bower Breast Cancer in Younger Women: Reproductive and Late Health Effects of Treatment J. Clin. Oncol., November 15, 2003; 21(22): 4184 - 4193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Bower, P. A. Ganz, N. Aziz, and J. L. Fahey Fatigue and Proinflammatory Cytokine Activity in Breast Cancer Survivors Psychosom Med, July 1, 2002; 64(4): 604 - 611. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Ganz, K. A. Desmond, B. Leedham, J. H. Rowland, B. E. Meyerowitz, and T. R. Belin Quality of Life in Long-Term, Disease-Free Survivors of Breast Cancer: a Follow-up Study J Natl Cancer Inst, January 2, 2002; 94(1): 39 - 49. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Ganz Impact of Tamoxifen Adjuvant Therapy on Symptoms, Functioning, and Quality of Life J Natl Cancer Inst Monographs, December 1, 2001; 2001(30): 130 - 134. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Day, P. A. Ganz, and J. P. Costantino Tamoxifen and Depression: More Evidence From the National Surgical Adjuvant Breast and Bowel Project's Breast Cancer Prevention (P-1) Randomized Study J Natl Cancer Inst, November 7, 2001; 93(21): 1615 - 1623. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Fallowfield, A. Fleissig, R. Edwards, A. West, T. J. Powles, A. Howell, and J. Cuzick Tamoxifen for the Prevention of Breast Cancer: Psychosocial Impact on Women Participating in Two Randomized Controlled Trials J. Clin. Oncol., April 1, 2001; 19(7): 1885 - 1892. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Rowland, K. A. Desmond, B. E. Meyerowitz, T. R. Belin, G. E. Wyatt, and P. A. Ganz Role of Breast Reconstructive Surgery in Physical and Emotional Outcomes Among Breast Cancer Survivors J Natl Cancer Inst, September 6, 2000; 92(17): 1422 - 1429. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Ganz, G. A. Greendale, L. Petersen, L. Zibecchi, B. Kahn, and T. R. Belin Managing Menopausal Symptoms in Breast Cancer Survivors: Results of a Randomized Controlled Trial J Natl Cancer Inst, July 5, 2000; 92(13): 1054 - 1064. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Moinpour, L. C. Lovato, I. M. Thompson Jr, J. E. Ware Jr, P. A. Ganz, D. L. Patrick, S. A. Shumaker, G. W. Donaldson, A. Ryan, and C. A. Coltman Jr Profile of Men Randomized to the Prostate Cancer Prevention Trial: Baseline Health-Related Quality of Life, Urinary and Sexual Functioning, and Health Behaviors J. Clin. Oncol., May 9, 2000; 18(9): 1942 - 1953. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Bower, P. A. Ganz, K. A. Desmond, J. H. Rowland, B. E. Meyerowitz, and T. R. Belin Fatigue in Breast Cancer Survivors: Occurrence, Correlates, and Impact on Quality of Life J. Clin. Oncol., February 14, 2000; 18(4): 743 - 743. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Kahler, M. Lutke, J. Weckmuller, R. Koster, T. Meinertz, and C.W. Hamm Coronary angioplasty in octogenarians. Quality of life and costs Eur. Heart J., December 2, 1999; 20(24): 1791 - 1798. [Abstract] [PDF]
|
|
|
|
|
|
R. Day, P. A. Ganz, J. P. Costantino, W. M. Cronin, D. L. Wickerham, and B. Fisher Health-Related Quality of Life and Tamoxifen in Breast Cancer Prevention: A Report From the National Surgical Adjuvant Breast and Bowel Project P-1 Study J. Clin. Oncol., September 1, 1999; 17(9): 2659 - 2659. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Ganz, K. A. Desmond, T. R. Belin, B. E. Meyerowitz, and J. H. Rowland Predictors of Sexual Health in Women After a Breast Cancer Diagnosis J. Clin. Oncol., August 1, 1999; 17(8): 2371 - 2371. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. J. Burstein, S. Gelber, E. Guadagnoli, and J. C. Weeks Use of Alternative Medicine by Women with Early-Stage Breast Cancer N. Engl. J. Med., June 3, 1999; 340(22): 1733 - 1739. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. T. Chlebowski, D. E. Collyar, M. R. Somerfield, and D. G. Pfister American Society of Clinical Oncology Technology Assessment on Breast Cancer Risk Reduction Strategies: Tamoxifen and Raloxifene J. Clin. Oncol., June 1, 1999; 17(6): 1939 - 1939. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Mortimer, L. Boucher, J. Baty, D. L. Knapp, E. Ryan, and J. H. Rowland Effect of Tamoxifen on Sexual Functioning in Patients With Breast Cancer J. Clin. Oncol., May 1, 1999; 17(5): 1488 - 1488. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. I. Macgregor and V. C. Jordan Basic Guide to the Mechanisms of Antiestrogen Action Pharmacol. Rev., June 1, 1998; 50(2): 151 - 196. [Abstract] [Full Text] [PDF]
|
|